Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Dent Res ; 101(12): 1517-1525, 2022 11.
Article in English | MEDLINE | ID: mdl-35689405

ABSTRACT

Ameloblastoma (AB) is an odontogenic tumor that arises from ameloblast-lineage cells. Although relatively uncommon and rarely metastatic, AB tumors are locally invasive and destructive to the jawbone and surrounding structures. Standard-of-care surgical resection often leads to disfigurement, and many tumors will locally recur, necessitating increasingly challenging surgeries. Recent genomic studies of AB have uncovered oncogenic driver mutations, including in the mitogen-activated protein kinase (MAPK) and Hedgehog signaling pathways. Medical therapies targeting those drivers would be a highly desirable alternative or addition to surgery; however, a paucity of existing AB cell lines has stymied clinical translation. To bridge this gap, here we report the establishment of 6 new AB cell lines-generated by "conditional reprogramming"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO. Furthermore, in proof-of-principle studies, we use the new cell lines to investigate AB oncogene dependency and drug sensitivity. Among our findings, AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation. AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability. The novel cell line resource enables preclinical studies and promises to speed the translation of new molecularly targeted therapies for the management of ameloblastoma and related odontogenic neoplasms.


Subject(s)
Ameloblastoma , Odontogenic Tumors , Humans , Ameloblastoma/drug therapy , Ameloblastoma/genetics , Hedgehog Proteins , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins p21(ras) , Neoplasm Recurrence, Local , Odontogenic Tumors/genetics , Class I Phosphatidylinositol 3-Kinases/therapeutic use , Mitogen-Activated Protein Kinases , Mitogen-Activated Protein Kinase Kinases/therapeutic use , Cell Line
2.
Breast Cancer Res Treat ; 123(2): 397-404, 2010 Sep.
Article in English | MEDLINE | ID: mdl-19949854

ABSTRACT

Recent advances in the study of the tumor microenvironment have revealed significant interaction between tumor cells and their surrounding stroma in model systems. We have previously shown that two distinct stromal signatures derived from a macrophage (CSF1) response and a fibroblastic (DTF-like) response are present in subsets of invasive breast cancers and show a correlation with clinical outcome. In the present study we explore whether these signatures also exist in the stroma of ductal carcinoma in situ (DCIS). We studied the signatures by both gene expression profile analysis of a publically available data set of DCIS and by immunohistochemistry (IHC) on a tissue microarray of DCIS and invasive breast cancer cases. Both the gene expression and immunohistochemical data show that the macrophage response and fibroblast expression signatures are present in the stroma of subsets of DCIS cases. The incidence of the stromal signatures in DCIS is similar to the incidence in invasive breast cancer that we have previously reported. We also find that the macrophage response signature is associated with higher grade DCIS and cases which are ER and PR negative, whereas the fibroblast signature was not associated with any clinicopathologic features in DCIS. A comparison of 115 matched cases of DCIS and invasive breast cancer found a correlation between the type of stromal response in DCIS and invasive ductal carcinoma (IDC) within the same patient for both the macrophage response and the fibroblast stromal signatures (P = 0.03 and 0.08, respectively). This study is a first characterization of these signatures in DCIS. These signatures have significant clinicopathologic associations and tend to be conserved as the tumor progresses from DCIS to invasive breast cancer.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/chemistry , Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/chemistry , Carcinoma, Ductal, Breast/genetics , Carcinoma, Intraductal, Noninfiltrating/chemistry , Carcinoma, Intraductal, Noninfiltrating/genetics , Stromal Cells/chemistry , Biomarkers, Tumor/genetics , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Intraductal, Noninfiltrating/pathology , Disease Progression , Female , Fibroblasts/chemistry , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic , Genotype , Humans , Immunohistochemistry , Macrophages/chemistry , Neoplasm Invasiveness , Neoplasm Staging , Oligonucleotide Array Sequence Analysis , Phenotype , Stromal Cells/pathology , Tissue Array Analysis
3.
Oncogene ; 29(6): 845-54, 2010 Feb 11.
Article in English | MEDLINE | ID: mdl-19901961

ABSTRACT

Leiomyosarcoma (LMS) is a soft tissue tumor with a significant degree of morphologic and molecular heterogeneity. We used integrative molecular profiling to discover and characterize molecular subtypes of LMS. Gene expression profiling was performed on 51 LMS samples. Unsupervised clustering showed three reproducible LMS clusters. Array comparative genomic hybridization (aCGH) was performed on 20 LMS samples and showed that the molecular subtypes defined by gene expression showed distinct genomic changes. Tumors from the 'muscle-enriched' cluster showed significantly increased copy number changes (P=0.04). A majority of the muscle-enriched cases showed loss at 16q24, which contains Fanconi anemia, complementation group A, known to have an important role in DNA repair, and loss at 1p36, which contains PRDM16, of which loss promotes muscle differentiation. Immunohistochemistry (IHC) was performed on LMS tissue microarrays (n=377) for five markers with high levels of messenger RNA in the muscle-enriched cluster (ACTG2, CASQ2, SLMAP, CFL2 and MYLK) and showed significantly correlated expression of the five proteins (all pairwise P<0.005). Expression of the five markers was associated with improved disease-specific survival in a multivariate Cox regression analysis (P<0.04). In this analysis that combined gene expression profiling, aCGH and IHC, we characterized distinct molecular LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers.


Subject(s)
Gene Expression Profiling , Leiomyosarcoma/classification , Leiomyosarcoma/genetics , Biomarkers, Tumor/metabolism , Comparative Genomic Hybridization , Genomics , Humans , Immunohistochemistry , Leiomyosarcoma/diagnosis , Leiomyosarcoma/metabolism , Prognosis , Tissue Array Analysis
4.
Breast Cancer Res Treat ; 112(3): 453-9, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18193353

ABSTRACT

BACKGROUND: HER2 gene amplification and/or protein overexpression in breast cancer is associated with a poor prognosis and predicts response to anti-HER2 therapy. We examine the natural history of breast cancers in relationship to increased HER2 copy numbers in a large population-based study. PATIENTS AND METHODS: HER2 status was measured by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in approximately 1,400 breast cancer cases with greater than 15 years of follow-up. Protein expression was evaluated with two different commercially-available antibodies. RESULTS: We looked for subgroups of breast cancer with different clinical outcomes, based on HER2 FISH amplification ratio. The current HER2 ratio cut point for classifying HER2 positive and negative cases is 2.2. However, we found an increased risk of disease-specific death associated with FISH ratios of >1.5. An 'intermediate' group of cases with HER2 ratios between 1.5 and 2.2 was found to have a significantly better outcome than the conventional 'amplified' group (HER2 ratio >2.2) but a significantly worse outcome than groups with FISH ratios less than 1.5. CONCLUSION: Breast cancers with increased HER2 copy numbers (low level HER2 amplification), below the currently accepted positive threshold ratio of 2.2, showed a distinct, intermediate outcome when compared to HER2 unamplified tumors and tumors with HER2 ratios greater than 2.2. These findings suggest that a new cut point to determine HER2 positivity, at a ratio of 1.5 (well below the current recommended cut point of 2.2), should be evaluated.


Subject(s)
Genes, erbB-2 , Receptor, ErbB-2/genetics , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Cohort Studies , Female , Follow-Up Studies , Gene Amplification , Humans , Immunohistochemistry/methods , In Situ Hybridization, Fluorescence/methods , Multivariate Analysis , Prognosis , Proportional Hazards Models , Receptor, ErbB-2/biosynthesis , Receptor, ErbB-2/physiology , Receptors, Estrogen/metabolism , Treatment Outcome
5.
Kidney Int ; 70(2): 306-14, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16760908

ABSTRACT

Mechanisms regulating pregnancy-induced changes in renal function are incompletely understood. Few candidate genes have been identified and data suggest that alternate mechanisms remain to be elucidated. Our objective was to screen thousands of genes expressed in kidneys from mice throughout gestation to identify possible key regulators of renal function during pregnancy. Mouse complementary DNA microarrays were used to screen for differences in expression during pregnancy in C57BL/6 mice. Interesting candidate genes whose expression varied with pregnancy were further analyzed by reverse transcription-PCR and Northern blot. Expression was localized by in situ hybridization and immunohistochemistry. Follow-up immunohistochemical analyses in archival human kidney sections from the fetus, non-pregnant, and pregnant women were also performed. Histidine decarboxylase (HDC), the enzyme that synthesizes histamine, was markedly upregulated in the mouse kidney during pregnancy. HDC expression localized to proximal tubule cells of fetal and adult mice. Females showed strong expression in the juxtamedullary zone before pregnancy and upregulation in the superficial cortical zone (SCZ) by mid-gestation. Histamine colocalized with HDC. Male mice showed only low HDC expression. Similar expression patterns were observed in human kidneys. Our results show that HDC expression and histamine production are increased in the SCZ during pregnancy. If histamine acts as a vasodilator, we speculate that increasing production in the SCZ may increase renal blood flow to this zone and recruit superficial cortical nephrons during pregnancy.


Subject(s)
Gene Expression Regulation, Enzymologic , Histidine Decarboxylase/genetics , Kidney Cortex/enzymology , Pregnancy, Animal/physiology , Pregnancy/physiology , Adolescent , Adult , Animals , Child , Child, Preschool , Female , Histidine Decarboxylase/metabolism , Humans , Infant , Kidney Cortex/embryology , Kidney Tubules, Proximal/embryology , Kidney Tubules, Proximal/enzymology , Male , Mice , Mice, Inbred C57BL , Middle Aged , Nephrons/embryology , Nephrons/enzymology , Oligonucleotide Array Sequence Analysis , Up-Regulation/physiology
6.
Histopathology ; 48(1): 22-31, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16359534

ABSTRACT

Array technologies (gene array, tissue microarray and others) are being used in a growing number of research projects involving soft tissue tumours. Gene array techniques allow for measurements of RNA expression levels or gene copy number changes for a large number of genes in a single specimen. A complementary technique, tissue microarrays, allows for the measurement of expression of a single gene in a large number of specimens. These techniques and similar ones have created a fundamentally new approach to the investigation of soft tissue tumours. This review addresses some of the advantages, problems, and solutions to those problems that come with these technologies.


Subject(s)
Microarray Analysis/methods , Oligonucleotide Array Sequence Analysis/methods , Soft Tissue Neoplasms/diagnosis , Cluster Analysis , Gene Expression Profiling , Humans , Soft Tissue Neoplasms/genetics
7.
Mol Cell Biol ; 18(11): 6408-15, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9774656

ABSTRACT

A central unanswered question concerning the initial phases of V(D)J recombination has been at which step the 12/23 rule applies. This rule, which governs which variable (V), diversity (D), and joining (J) segments are able to pair during recombination, could operate at the level of signal sequence synapsis after RAG-HMG1 complex binding, signal nicking, or signal hairpin formation. It has also been unclear whether additional proteins are required to achieve adherence to the 12/23 rule. We developed a novel system for the detailed biochemical analysis of the 12/23 rule by using an oligonucleotide-based substrate that can include two signals. Under physiologic conditions, we found that the complex of RAG1, RAG2, and HMG1 can successfully recapitulate the 12/23 rule with the same specificity as that seen intracellularly and in crude extracts. The cleavage complex can bind and nick 12x12 and 23x23 substrates as well as 12x23 substrates. However, hairpin formation occurs at both of the signals only on 12x23 substrates. Moreover, under physiologic conditions, the presence of a partner 23-bp spacer suppresses single-site hairpin formation at a 12-bp spacer and vice versa. Hence, this study illustrates that synapsis suppresses single-site reactions, thereby explaining the high physiologic ratio of paired versus unpaired V(D)J recombination events in lymphoid cells.


Subject(s)
DNA-Binding Proteins/metabolism , Genes, Immunoglobulin/genetics , High Mobility Group Proteins/metabolism , Homeodomain Proteins/metabolism , Immunoglobulin Variable Region/genetics , Recombination, Genetic/genetics , Animals , DNA Nucleotidyltransferases/genetics , Mice , Nucleic Acid Conformation , Oligodeoxyribonucleotides/metabolism , VDJ Recombinases
8.
Mol Cell Biol ; 18(10): 5908-20, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9742108

ABSTRACT

DNA-dependent protein kinase (DNA-PK) is the only eukaryotic protein kinase known to be specifically activated by double-stranded DNA (dsDNA) termini, accounting for its importance in repair of dsDNA breaks and its role in physiologic processes involving dsDNA breaks, such as V(D)J recombination. In this study we conducted kinase and binding analyses using DNA-PK on DNA termini of various lengths in the presence and absence of Ku. We confirmed our previous observations that DNA-PK can bind DNA termini in the absence of Ku, and we determined rate constants for binding. However, in the presence of Ku, DNA-PK can assume either a productive or a nonproductive configuration, depending on the length of the DNA terminus. For dsDNA greater than 26 bp, the productive mode is achieved and Ku increases the affinity of the DNA-PK for the Ku:DNA complex. The change in affinity is achieved by increases in both the kinetic association rate and reduction in the kinetic dissociation rate. For dsDNA smaller than 26 bp, the nonproductive mode, in which DNA-PK is bound to Ku:DNA but is inactive as a kinase, is assumed. Both the productive and nonproductive configurations are likely to be of physiologic importance, depending on the distance of the dsDNA break site to other protein complexes, such as nucleosomes.


Subject(s)
Antigens, Nuclear , DNA Helicases , DNA-Binding Proteins/metabolism , Nuclear Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , DNA/metabolism , DNA-Activated Protein Kinase , Enzyme Activation , HeLa Cells , Humans , Ku Autoantigen , Mass Spectrometry , Nucleic Acid Conformation , Structure-Activity Relationship
9.
Curr Opin Immunol ; 10(2): 172-80, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9602306

ABSTRACT

Two specialized forms of site-directed double-strand (ds) DNA breakage and rejoining are part of the physiologic program of lymphocytes. One is recombination of the V, D and J gene sequences, termed V(D)J recombination, occurring during early B- and T-cell development, and the other is class-switch recombination occurring exclusively in mature B cells. For V(D)J recombination significant progress has been made recently elucidating the biochemistry of the reaction. In particular our understanding of how DNA ds breaks are both generated and rejoined has increased. For class-switch recombination no definitive information is known about the nucleases required for making the ds breaks, but recent evidence suggests that the joining phase shares activities also required for V(D)J recombination and general DNA ds break repair.


Subject(s)
Receptors, Antigen, B-Cell/genetics , Receptors, Antigen, T-Cell/genetics , Animals , Gene Rearrangement, B-Lymphocyte , Gene Rearrangement, T-Lymphocyte , Humans , Immunoglobulin Class Switching/genetics , Immunoglobulin Variable Region/genetics , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...